SCILEX HOLDING CO

SCLXNASDAQ

🏆 #3738 by market capEarnings Sep 2US Equity

$6.53▼ $0.18 (−2.68%)

Live

1h—

24h▼ 2.7%

7d▲ 0.7%

14d▼ 1.7%

30d▼ 30.1%

1y▼ 62.9%

🏦Market Cap

$55M

Small Cap

📈Revenue Growth (YoY)

-46.5%

Declining

📊Gross Margin

55.0%

Healthy

💵FCF Margin

-19.5%

Thin

⚖️P/S Ratio

1.6x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $6.49 – $6.62
52-Week Range: $2.62 – $21.34
Volume: $2.00B
Avg Volume: $2.54B
Shares Outstanding: 8.5M
Next Earnings: Sep 30, 2026

Fundamentals Snapshot

Annual Revenue: $30M
Last Q Revenue: $9M
P/E Ratio: -0.2
P/S Ratio: 1.6x
EPS (TTM): $-60.90
Dividend Yield: 0.00%

Why Investors Own SCLX

✓High-growth profile — revenue up -0.9% YoY with expanding US Equity exposure.
✓Healthy economics — 60% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$30M▲ +1.8% YoY

Gross Margin (TTM)

60.4%▼ −0.2% YoY

Operating Income (TTM)

$10M▲ +1.8% YoY

Free Cash Flow (TTM)

$3M▲ +1.8% YoY

About SCILEX HOLDING CO

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

🦦